Insulin-Like Growth Factor I Deficiency: Clinical Trials

6 trials for Insulin-Like Growth Factor I Deficiency, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 unknown, 2 terminated, 1 recruiting. 2 Not applicable, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Not applicable2Unknown 2
Phase 21Terminated 1

Follow Insulin-Like Growth Factor I Deficiency: new trials by email Literature Review of Insulin-Like Growth Factor I Deficiency trials Research Report on Insulin-Like Growth Factor I Deficiency

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effect of a HIIT Program on Quality of Life, Executive Functions, and IGF-1 Response in Sedentary Young University Women
HIIT, HIIT+PA, CON - Insulin Growth Factor I Deficiency, IGF1 Deficiency
Not applicableUnknownUniversity of Seville752022-10-152022-12-08
AR, IGF-IR, IR and Peripheral Artery Disease
arterial reconstructive open surgery - Androgen Receptor Abnormal, Insulin-Like Growth Factor I Deficiency
UnknownUniversity of Catanzaro302018-08-012021-01-14
Effect of Maternal BMI and Type of Infants Feeding on IGF-1 in Infant
level of IGF-1 in infants - IGF1 Deficiency
Not applicableUnknownAssiut University402017-12-012017-09-07
IGF-1, IGFBP3, ALS Normative Ranges in Healthy Pediatric Spanish Population
IGF-1 Deficiency
TerminatedIpsen3042012-07-012019-01-11
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Increlex® - IGF1 Deficiency
RecruitingEsteve Pharmaceuticals, S.A.5002008-12-092026-02-06
rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency
NutropinAq® (Somatropin [rDNA origin]), Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin]) - Insulin-like Growth Factor-1 Deficiency
Phase 2TerminatedIpsen1062007-12-012023-03-30

Narrower conditions

Bulbo-Spinal Atrophy, X-Linked (1)  ·  Insulin Receptor, Defect in (1)  ·  Peripheral Arterial Disease (1)  ·  Puberty, Delayed (1)

Broader conditions

Arterial Occlusive Diseases (1)  ·  Arteriosclerosis (1)  ·  Atherosclerosis (1)  ·  Cardiovascular Diseases (1)  ·  Central Nervous System Diseases (1)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)  ·  Endocrine System Diseases (1)  ·  Genetic Diseases, Inborn (1)  ·  Genetic Diseases, X-Linked (1)  ·  Gonadal Disorders (1)  ·  Heredodegenerative Disorders, Nervous System (1)  ·  Motor Neuron Disease (1)  ·  Muscular Atrophy, Spinal (1)  ·  Nervous System Diseases (1)  ·  Neurodegenerative Diseases (1)

Interventions

mecasermin (2)  ·  Human Growth Hormone (1)  ·  Injections (1)

Sponsors

Ipsen (2)  ·  Assiut University (1)  ·  Esteve Pharmaceuticals, S.A. (1)  ·  University of Catanzaro (1)  ·  University of Seville (1)

Countries

Spain (3)  ·  Italy (2)  ·  United States (2)  ·  Austria (1)  ·  France (1)  ·  French Guiana (1)  ·  Germany (1)  ·  Martinique (1)  ·  Poland (1)  ·  Sweden (1)  ·  United Kingdom (1)

Top investigators

Manuel Jesus Jimenez Roldan (1)  ·  Marcello Maggiolini, M.D. (1)  ·  Raffaele Serra, M.D., Ph.D. (1)

Results publications

PMID 11726732, PMID 33401605, PMID 33434161, PMID 35250870, PMID 37579214, PMID 3956421, PMID 40626687

NIH funding

2019 (1)